$64.9 Million is the total value of Knoll Capital Management, LLC's 26 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 52.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALDX | Buy | Aldeyra Therapeutics Inc | $20,526,898 | +51.4% | 2,067,160 | +6.1% | 31.64% | +3.4% |
| BHVN | Biohaven Pharmactl Hldg Co L | $6,152,764 | -1.6% | 450,422 | 0.0% | 9.48% | -32.8% | |
| AVDL | New | Avadel Pharmaceuticals Plccall | $4,580,000 | – | 500,000 | +100.0% | 7.06% | – |
| VRNA | Buy | Verona Pharmasponsored ads | $4,016,000 | +61.1% | 200,000 | +109.7% | 6.19% | +10.0% |
| GDX | Vaneck Gold Miners ETFgold miners etf | $2,971,347 | +12.9% | 91,850 | 0.0% | 4.58% | -22.9% | |
| ENTX | Entera Bio Ltd | $2,881,759 | +111423.2% | 2,484,275 | 0.0% | 4.44% | +73916.7% | |
| APLT | Buy | Applied Therapeutics Inc | $2,797,950 | +50.3% | 3,450,000 | +40.8% | 4.31% | +2.6% |
| SIL | Global X Silver Miners ETF 37954Y848global x silver | $2,755,584 | +9.1% | 89,700 | 0.0% | 4.25% | -25.5% | |
| GDXJ | Vaneck Junior Gold Miners ETFjunior hold mine | $2,099,425 | +10.8% | 53,150 | 0.0% | 3.24% | -24.3% | |
| OCUL | New | Ocular Therapeutix Inc. | $1,504,000 | – | 200,000 | +100.0% | 2.32% | – |
| OR | Buy | OSISKO GOLD ROYALTIES LTD | $1,272,000 | +109.3% | 400,000 | +70.2% | 1.96% | +43.0% |
| TMO | Thermo Fischer Scientific Inc | $1,213,800 | +5.0% | 2,100 | 0.0% | 1.87% | -28.3% | |
| BAH | Booz Allen Hamilton HLDG CORcl a | $1,204,970 | -11.3% | 13,000 | 0.0% | 1.86% | -39.4% | |
| V | Visa | $1,093,481 | +8.5% | 4,850 | 0.0% | 1.68% | -25.9% | |
| CVS | CVS Health Corp | $1,077,495 | -20.3% | 14,500 | 0.0% | 1.66% | -45.5% | |
| New | Omega Therapeutics Inc. | $1,043,250 | – | 173,010 | +100.0% | 1.61% | – | |
| SILV | New | Silvercrest Metals Inc CAD | $1,043,614 | – | 170,000 | +100.0% | 1.61% | – |
| SA | Buy | SEABRIDGE GOLD INC | $1,036,000 | +100.9% | 80,000 | +95.1% | 1.60% | +37.2% |
| FNV | New | Franco Nev Corp CAD | $1,020,600 | – | 7,000 | +100.0% | 1.57% | – |
| MO | Altria Group Inc | $1,012,874 | -2.4% | 22,700 | 0.0% | 1.56% | -33.3% | |
| NOC | New | Northrop Grumman Corp | $999,623 | – | 2,165 | +100.0% | 1.54% | – |
| ORGS | Orgenesis, Inc. | $748,990 | -39.5% | 634,738 | 0.0% | 1.15% | -58.7% | |
| ALT | Altimmune Inc | $733,706 | -74.3% | 173,864 | 0.0% | 1.13% | -82.5% | |
| OCUL | New | Ocular Therapeutix Inc.call | $504,866 | – | 95,800 | +100.0% | 0.78% | – |
| OCUP | New | Ocuphire Pharma Inc. | $375,000 | – | 100,000 | +100.0% | 0.58% | – |
| HOOK | Buy | HOOKIPA PHARMA | $220,800 | +445.2% | 300,000 | +500.0% | 0.34% | +273.6% |
| Exit | Anavex Life Sciences Corp | $0 | – | -10,681 | -100.0% | -0.22% | – | |
| BX | Exit | Blackstone Group LP | $0 | – | -10,000 | -100.0% | -1.67% | – |
| AVDL | Exit | Avadel Pharmaceuticals Plcsponsored adr | $0 | – | -150,000 | -100.0% | -2.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.